Drug Trial Radar · NCT00006462
Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Last checked: Nov 20, 2026Latest source record: Feb 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 2001
Primary completion
Aug 2003
Study completion Sep 2006
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating children who have relapsed or refractory acute lymphoblastic leukemia or acute myelogenous leukemia.
Conditions
- Leukemia
Interventions
gemcitabine hydrochlorideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the response rate to Gemcitabine
Locations
225 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama
University of South Alabama Medical Center
Mobile, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
Arizona Cancer Center
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Southern California Permanente Medical Group
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Rebecca and John Moores UCSD Cancer Center
La Jolla, California
Loma Linda University Medical Center
Loma Linda, California
Jonathan Jaques Children's Cancer Center
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
Children's Hospital Central California
Madera, California
Children's Hospital of Oakland
Oakland, California
Chao Family Comprehensive Cancer Center
Orange, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital at Stanford
Palo Alto, California
Sutter Cancer Center
Sacramento, California
University of California Davis Medical Center
Sacramento, California
Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego
San Diego, California
Children's Hospital San Diego
San Diego, California
Kaiser Permanente Medical Center - San Francisco Geary Campus
San Francisco, California
UCSF Comprehensive Cancer Center
San Francisco, California
Santa Barbara Cottage Hospital
Santa Barbara, California
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California
David Grant Medical Center
Travis Air Force Base, California
Children's Hospital of Denver
Denver, Colorado
Presbyterian-St Luke's Medical Center
Denver, Colorado
University of Connecticut Health Center
Farmington, Connecticut
Yale Comprehensive Cancer Center
New Haven, Connecticut
Alfred I. Dupont Institute
Wilmington, Delaware
Lombardi Cancer Center
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Walter Reed Army Medical Center
Washington D.C., District of Columbia
Broward General Medical Center
Fort Lauderdale, Florida
Children's Hospital of Southwest Florida
Fort Myers, Florida
Shands Hospital and Clinics, University of Florida
Gainesville, Florida
Joe DiMaggio Children's Hospital at Memorial
Hollywood, Florida
Nemours Children's Clinic
Jacksonville, Florida
Showing 40 of 225 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.